SequelSEC

CERENOME, INC. CNSY

Surgical & Medical Instruments & Apparatus · CIK 0001095981 · Fiscal year ends 1231

Revenue
$5.21M
Fiscal year ended 2025-12-31
Operating income
-$15.30M
Fiscal year ended 2025-12-31
Free cash flow
-$20.84M
Fiscal year ended 2025-12-31

CERENOME, INC. (CNSY) reported revenue of $5.21M and net income of -$22.39M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from CERENOME, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

CERENOME, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue$5.21M$5.82M$4.91M$3.67M$2.69M$4.66M$4.84M$4.95M
Cost of revenueUnavailableUnavailableUnavailable$1.15MUnavailable$2.72M$3.19M$2.94M
Gross profitUnavailableUnavailableUnavailable$2.52MUnavailable$1.94M$1.65M$2.01M
Operating income-$15.30M-$14.70M-$13.32M-$8.76M-$20.68M-$19.71M-$15.29M-$32.44M
Net income-$22.39M-$12.98M-$13.32M-$12.63M-$22.69M-$22.05M-$18.74M-$37.37M
Research & development$8.38M$10.58M$9.69M$5.52M$11.68M$16.20M$19.00M$15.10M
Weighted-average diluted sharesshares 77.80Mshares 7.70Mshares 3.14MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$22.39M-$12.98MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0Unavailable
Diluted EPS$-0.29$-2.34$-4.24UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable$6.22M$11.19M$12.17M$12.43M$22.36M
General & administrative$12.13M$9.94M$8.54M$5.58M$7.59M$8.56M$9.76M$15.95M
Selling & marketingUnavailableUnavailableUnavailable$643.00K$3.59M$3.61M$2.66M$6.41M

Balance

CERENOME, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$4.26M$76.00K$8.55M$5.26M$9.55M$12.60M$14.34M$14.62M
Total assets$16.32M$6.63M$11.39M$23.99M$31.62M$34.61M$37.70M$38.72M
Current assets$15.17M$5.26M$9.83M$9.65M$14.86M$18.75M$21.24M$21.69M
Total liabilities$12.33M$15.58M$12.74M$18.77M$18.62M$23.62M$25.49M$44.42M
Current liabilities$12.31M$15.55M$10.73M$17.56M$18.41M$12.50M$8.44M$15.92M
Total equity incl. NCI$4.00M-$8.95M-$1.35M$5.22M$13.00M$10.99M$12.21M-$5.70M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable$107.00K$3.18M$3.72M$4.30M$4.83M
Accounts receivableUnavailableUnavailableUnavailable$178.00K$145.00K$1.24M$1.05M$1.24M
Goodwill$372.00K$372.00K$372.00K$372.00K$3.92M$3.92M$3.92M$3.92M
Long-term debtUnavailableUnavailableUnavailableUnavailable$0$11.01M$16.68M$18.04M
Accounts payable$3.28M$9.47M$4.76M$721.00K$1.30M$1.33M$1.01M$949.00K

Cash flow

CERENOME, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$20.78M-$10.55M-$12.85M-$11.98M-$18.13MUnavailableUnavailableUnavailable
Capital expenditures$67.00K$146.00K$160.00K$133.00K$295.00K$67.00K$611.00K$764.00K
Investing cash flow-$854.00K-$4.11M-$160.00K-$133.00K-$1.38MUnavailableUnavailable-$1.34M
Financing cash flow$30.31M$6.19M$3.44M$7.17M$16.82MUnavailableUnavailableUnavailable
Net change in cash$8.68M-$8.48M-$9.57M-$4.92M-$2.68M-$1.78M-$284.00K-$884.00K
Stock-based compensation$1.54M$550.00K$569.00K$355.00K$753.00K$1.08M$2.04M$3.10M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$445.00K$872.00K$628.00K$2.00M$2.15M$1.18M$1.09M$779.00K

Derived

CERENOME, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Free cash flow-$20.84M-$10.70M-$13.01M-$12.11MUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable68.7%Unavailable41.7%34.1%40.6%
Operating margin-293.5%-252.3%-271.1%Unavailable-769.2%-423.2%-316.0%-654.9%
FCF margin-399.8%-183.7%-264.8%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue29.5%9.4%11.6%Unavailable28.0%23.2%42.2%62.6%
Current ratio1.23x0.34x0.92x0.55x0.81x1.50x2.52x1.36x
Revenue YoY growth-10.5%18.5%Unavailable36.5%-42.2%-3.8%-2.3%Unavailable
Net margin-429.4%-222.8%-271.0%Unavailable-843.7%-473.5%-387.4%-754.5%
R&D / revenue160.7%181.7%197.2%Unavailable434.3%347.9%392.7%305.0%
CapEx / revenue1.3%2.5%3.3%UnavailableUnavailable1.4%12.6%15.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CNSY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-30View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2017-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.